Teva Pharmaceutical Industries Limited (NYSE:TEVA) EVP Sells $327,075.56 in Stock

by · The Cerbat Gem

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Teva Pharmaceutical Industries Trading Up 0.3 %

TEVA stock traded up $0.05 during trading on Thursday, reaching $17.08. 5,419,790 shares of the stock traded hands, compared to its average volume of 9,216,287. The firm has a market capitalization of $19.35 billion, a PE ratio of -20.03, a P/E/G ratio of 1.31 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 52-week low of $9.35 and a 52-week high of $19.31. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business’s 50 day moving average price is $17.72 and its 200-day moving average price is $17.30.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors have recently made changes to their positions in TEVA. New Covenant Trust Company N.A. acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $28,000. EntryPoint Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $30,000. UMB Bank n.a. increased its position in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $48,000. Finally, Smithfield Trust Co raised its position in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TEVA shares. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group lifted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average price target of $19.67.

View Our Latest Stock Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

See Also